Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jul;60(1):89–92. doi: 10.1038/bjc.1989.226

A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients.

M C Launay 1, G Milano 1, A Iliadis 1, M Frenay 1, N Namer 1
PMCID: PMC2247334  PMID: 2803920

Abstract

The aim of this study was to find a procedure allowing estimation of individual pharmacokinetic parameters for adriamycin with minimal cost and disturbance for the patient. Twenty-five patients with breast cancer were treated by short infusion of adriamycin at a dose of 12 mg m-2 week-1 (41 courses). Population characteristics were determined on 15 randomly chosen courses (10 patients, group I) in order to define two optimal sampling times (26 min and 24 h) and to perform Bayesian estimation on the remaining 26 courses (17 patients, group II). For patients of group II, Bayesian estimation (BE) associated with a reduced sub-optimal sampling protocol (20 min and 24 h) was compared with maximum likelihood estimation (MLE), the classical procedure. Regression analysis of clearance values obtained after BE versus MLE indicated a high correlation coefficient (r = 0.969) with the slope (a = 0.991 +/- 0.085) and the intercept (b = 2.271 +/- 4.810) close to 1 and 0 respectively. This original method is thus valid to measure accurately adriamycin clearance; it improves patient comfort and can be used routinely.

Full text

PDF
91

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. D'Argenio D. Z., Khakmahd K. Adaptive control of theophylline therapy: importance of blood sampling times. J Pharmacokinet Biopharm. 1983 Oct;11(5):547–559. doi: 10.1007/BF01062211. [DOI] [PubMed] [Google Scholar]
  2. Eichholtz-Wirth H. Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. Br J Cancer. 1980 Jun;41(6):886–891. doi: 10.1038/bjc.1980.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Iliadis A., Bachir-Raho M., Bruno R., Favre R. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. J Pharmacokinet Biopharm. 1985 Feb;13(1):101–115. doi: 10.1007/BF01073659. [DOI] [PubMed] [Google Scholar]
  4. Kaye S. B., Cummings J., Kerr D. J. How much does liver disease affect the pharmacokinetics of adriamycin? Eur J Cancer Clin Oncol. 1985 Aug;21(8):893–895. doi: 10.1016/0277-5379(85)90103-8. [DOI] [PubMed] [Google Scholar]
  5. Powis G. Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol. 1985;14(3):177–183. doi: 10.1007/BF00258112. [DOI] [PubMed] [Google Scholar]
  6. Ratain M. J., Staubus A. E., Schilsky R. L., Malspeis L. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res. 1988 Jul 15;48(14):4127–4130. [PubMed] [Google Scholar]
  7. Ratain M. J., Vogelzang N. J. Limited sampling model for vinblastine pharmacokinetics. Cancer Treat Rep. 1987 Oct;71(10):935–939. [PubMed] [Google Scholar]
  8. Ritch P. S., Occhipinti S. J., Skramstad K. S., Shackney S. E. Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure. Cancer Treat Rep. 1982 May;66(5):1159–1168. [PubMed] [Google Scholar]
  9. Robert J., Illiadis A., Hoerni B., Cano J. P., Durand M., Lagarde C. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol. 1982 Aug;18(8):739–745. doi: 10.1016/0277-5379(82)90072-4. [DOI] [PubMed] [Google Scholar]
  10. Rodvold K. A., Rushing D. A., Tewksbury D. A. Doxorubicin clearance in the obese. J Clin Oncol. 1988 Aug;6(8):1321–1327. doi: 10.1200/JCO.1988.6.8.1321. [DOI] [PubMed] [Google Scholar]
  11. Sheiner L. B., Beal S. L. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981 Oct;9(5):635–651. doi: 10.1007/BF01061030. [DOI] [PubMed] [Google Scholar]
  12. Sheiner L. B., Beal S. L. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm. 1985 Apr;13(2):185–201. doi: 10.1007/BF01059398. [DOI] [PubMed] [Google Scholar]
  13. Sheiner L. B., Beal S. L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 Aug;9(4):503–512. doi: 10.1007/BF01060893. [DOI] [PubMed] [Google Scholar]
  14. Sheiner L. B., Beal S., Rosenberg B., Marathe V. V. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979 Sep;26(3):294–305. doi: 10.1002/cpt1979263294. [DOI] [PubMed] [Google Scholar]
  15. Vozeh S., Steiner C. Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis. J Pharmacokinet Biopharm. 1987 Oct;15(5):511–528. doi: 10.1007/BF01061760. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES